Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 51407-837

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 51407-837). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-836-05lb (Lurasidone HCI)

This is information regarding a medication called Lurasidone Hydrochloride in tablet form. Each tablet contains 20 mg of lurasidone HCI. It includes instructions for pharmacists to dispense a Medication Guide to each patient and store the medication in a tight, light-resistant container. The medication should be kept out of the reach of children and stored at 20° - 25°C (68° - 77°F). The contact information for the marketer is GSMS, Incorporated Camarillo, CA 93012 USA.*

FDA Label Image

51407-837-05lb (Lurasidone HCI)

The text provides information on Lurasidone Hydrochloride tablets with 60 mg strength, each tablet equivalent to 55.87 mg of lurasidone. The medication guide should be dispensed to each patient, and the complete prescribing information should be followed for dosage. The tablets are to be stored in a tightly closed, light-resistant container at room temperature. The medication is available in a bottle containing 500 tablets and is for prescription use only. Further information and the medication guide can be found at the provided URL.*

FDA Label Image

51407-838-05lb (Lurasidone HCI)

Each tablet contains 120 mg of lurasidone HCI (equivalent to 111.73 mg of lurasidone). This medication is dispensed in a tight, light-resistant container as per USP standards. It is important to keep the container tightly closed and out of reach of children. The pharmacist should provide a Medication Guide to each patient and store the medication at a temperature between 20°C to 25°C (68°F to 77°F). For more information, consult the accompanying Prescribing Information.*

FDA Label Image

Avetlogo-mg (Avetlogo mg)

FDA Label Image

Avet-logo (Avet Logo)

FDA Label Image

Chemical-structure (Chemical Structure)

FDA Label Image

Figure-1 (Figure 1)

The text mentions the impact of different drugs on the pharmacokinetics of Lurasidone. It provides information on the fold change and 90% confidence intervals for drugs categorized as Strong CYP3A4 Inhibitors (Ketoconazole), Moderate CYP3A4 Inhibitors (Diltiazem), and Strong CYP3A4 Inducers (Rifampin). The text also references the effect of Lithium on Cmax and AUC. The data indicates how these drugs influence Lurasidone pharmacokinetics (PK) relative to Lurasidone alone.*

FDA Label Image

Figure-2 (Figure 2)

This text provides information on interacting drugs, including P-gp substrates like digoxin, CYP3A4 substrates such as midazolam, an oral contraceptive containing ethinyl estradiol and norelgestromin, and lithium. It also mentions pharmacokinetic parameters like Cmax, AUC, and Ctrough, along with fold change and 90% confidence interval. The data indicates changes in these parameters when these drugs are taken together.*

FDA Label Image

Figure-3 (Figure 3)

This text seems to contain information about renal impairment, gender comparison between Asian and Caucasian populations in relation to pharmacokinetics, and variability in fold change relative to reference values. It provides insights into the impact of renal and hepatic impairment on moderate to severe levels and their association with pharmacokinetics. Additionally, it suggests the comparison of these factors between different ethnic groups.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.